Cogent Biosciences Reports Unregistered Equity Sales
Ticker: COGT · Form: 8-K · Filed: Mar 22, 2024 · CIK: 1622229
| Field | Detail |
|---|---|
| Company | Cogent Biosciences, INC. (COGT) |
| Form Type | 8-K |
| Filed Date | Mar 22, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: unregistered-sales, equity, dilution
TL;DR
Cogent sold unregistered equity, watch for dilution.
AI Summary
Cogent Biosciences, Inc. filed an 8-K on March 21, 2024, reporting unregistered sales of equity securities. The company, formerly Unum Therapeutics Inc., is incorporated in Delaware and based in Waltham, Massachusetts.
Why It Matters
This filing indicates potential dilution for existing shareholders due to the issuance of new equity without a prior public registration.
Risk Assessment
Risk Level: medium — Unregistered sales can signal financial distress or a need for quick capital, potentially impacting stock value.
Key Players & Entities
- Cogent Biosciences, Inc. (company) — Registrant
- Unum Therapeutics Inc. (company) — Former company name
- March 21, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Waltham, Massachusetts (location) — Company address
FAQ
What type of equity securities were sold in the unregistered offering?
The filing does not specify the type of equity securities sold in the unregistered offering.
Were there any specific dollar amounts associated with the unregistered sales?
The filing does not disclose specific dollar amounts for the unregistered sales of equity securities.
Who were the purchasers in the unregistered sale of equity securities?
The filing does not identify the purchasers of the unregistered equity securities.
What is the reason for the unregistered sale of equity securities?
The filing does not provide a specific reason for the unregistered sale of equity securities.
When did Cogent Biosciences, Inc. change its name from Unum Therapeutics Inc.?
Cogent Biosciences, Inc. changed its name from Unum Therapeutics Inc. on April 2, 2018.
Filing Stats: 1,148 words · 5 min read · ~4 pages · Grade level 13.1 · Accepted 2024-03-22 08:33:30
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 Par Value COGT The Nasdaq Global Se
Filing Documents
- d796451d8k.htm (8-K) — 31KB
- d796451dex32.htm (EX-3.2) — 6KB
- d796451dex101.htm (EX-10.1) — 43KB
- 0001193125-24-074628.txt ( ) — 220KB
- cogt-20240321.xsd (EX-101.SCH) — 3KB
- cogt-20240321_lab.xml (EX-101.LAB) — 18KB
- cogt-20240321_pre.xml (EX-101.PRE) — 11KB
- d796451d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 3.1* Certificate of Designations of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant's Form 8-K (File No. 001-38443) filed on February 14, 2024) 3.2 Certificate of Amendment to the Certificate of Designations of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock 10.1 Form of Exchange Agreement, dated March 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Previously filed.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 22, 2024 COGENT BIOSCIENCES, INC. By: /s/ Evan Kearns Evan Kearns Chief Legal Officer